Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clinical Genetics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    137 result(s) found for: Clinical Genetics. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2012-002873-77 Sponsor Protocol Number: 2013.2015 Start Date*: 2013-01-25
    Sponsor Name:University Medical Center Groningen, Department of Genetics
    Full Title: The effect of intranasal insulin on development and behaviour of children with Phelan-McDermid syndrome
    Medical condition: Phelan-McDermid syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001721-26 Sponsor Protocol Number: B9R-EW-GDFC(a) Start Date*: 2006-09-25
    Sponsor Name:UAB “Eli Lilly Lietuva”
    Full Title: The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)
    Medical condition: Short Stature
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004016-26 Sponsor Protocol Number: Clin_COVID-19_Corok Start Date*: 2021-10-18
    Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital
    Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection"
    Medical condition: None
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000155-41 Sponsor Protocol Number: 1 Start Date*: 2019-01-10
    Sponsor Name:Department of Medical and Clinical Genetics, University of Helsinki
    Full Title: The effect of vitamin C on the gene methylation load in patients with TET2 mutations
    Medical condition: germline TET-2 gene mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001946-17 Sponsor Protocol Number: SGNLVA-005 Start Date*: 2019-11-29
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
    Medical condition: Multiple Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002812-27 Sponsor Protocol Number: CEP-1347-201 Start Date*: 2005-05-04
    Sponsor Name:deCODE genetics ehf.
    Full Title: A prospective, randomised, double-blind, placebo-controlled, parallel group dose ranging study in asthma patients in Iceland to assess the safety, tolerability and efficacy of the MLK inhibitor, CE...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005526-29 Sponsor Protocol Number: VP-VLY-686-3501 Start Date*: 2021-03-31
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: ODYSSEY: A randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe ...
    Medical condition: inflammatory lung injury associated with severe COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-006102-23 Sponsor Protocol Number: ImmuneRaRe_RF-2019-12369708 Start Date*: 2021-10-13
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predicti...
    Medical condition: HIV-1 positive subjects treated with effective antiretroviral therapy during the acute phase of HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005763-24 Sponsor Protocol Number: CTSUBEST-D Start Date*: 2012-06-28
    Sponsor Name:University of Oxford
    Full Title: BEST-D (Biochemical efficacy and safety trial of vitamin D): a dose-finding trial assessing biochemical and vascular effects of high dose vitamin D
    Medical condition: BEST-D is a trial assessing the efficacy and safety of vitamin D3 supplements (two doses 50μg and 100μg); hence there are no specific medical conditions under study. Volunteers aged 65 years or old...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10047630 Vitamin depletion LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001238-21 Sponsor Protocol Number: 2020-SESGEN Start Date*: 2021-07-06
    Sponsor Name:Institute of Health and Biomedical Research of Alicante
    Full Title: Gender biases in pain medicine: from omics to healthcare.
    Medical condition: The medical condition to be evaluated is the analgesic response of people with chronic low back pain who are going to be treated with opioids, guided by omics sciences (pharmacogenetics, epigeneti...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003540-12 Sponsor Protocol Number: NLG2101 Start Date*: 2015-03-02
    Sponsor Name:NewLink Genetics Corporation
    Full Title: A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination with a Taxane Chemotherapy in Metastatic Breast Cancer
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002402-36 Sponsor Protocol Number: IMP 11815/Amend.01/Amend.2 Start Date*: 2006-04-18
    Sponsor Name:Talecris Biotherapeutics
    Full Title: Multi-center, open-label trial to evaluate the safety and tolerability of Alpha-1 MP in subjects with Alpha-1-antitrypsin (α1AT) deficiency. STAMP: Safety and Tolerability of Alpha-1 MP
    Medical condition: Alpha-1 Antitrypsin (AAT) deficiency
    Disease: Version SOC Term Classification Code Term Level
    9 10001806 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001671-51 Sponsor Protocol Number: SGN35-023 Start Date*: 2016-06-15
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF RITUXIMAB AND BENDAMUSTINE WITH OR WITHOUT BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY CD30-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA
    Medical condition: i) Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma ii) follicular non-Hodgkin lymphoma (NHL) grade 3b
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006323-31 Sponsor Protocol Number: D1532C00016 Start Date*: 2009-05-19
    Sponsor Name:AstraZeneca AB
    Full Title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line...
    Medical condition: 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003032-23 Sponsor Protocol Number: AADC-010 Start Date*: 2019-10-09
    Sponsor Name:National Taiwan University Hospital
    Full Title: A Phase I/II Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC
    Medical condition: Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003072-39 Sponsor Protocol Number: NTUH-AADC-011 Start Date*: 2019-10-09
    Sponsor Name:National Taiwan University Hospital
    Full Title: A Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion
    Medical condition: Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002707-10 Sponsor Protocol Number: SJ-596 Start Date*: 2018-04-10
    Sponsor Name:Regional Dementia Research Centre, Dept of Neurology
    Full Title: Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance
    Medical condition: Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10012284 Dementia due to Parkinson's disease LLT
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    20.0 10029205 - Nervous system disorders 10075174 Mixed dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001482-57 Sponsor Protocol Number: SAKK_41/13-Aspirin Start Date*: 2016-09-19
    Sponsor Name:SAKK Swiss Group for Clinical Cancer Research
    Full Title: Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial
    Medical condition: PIK3CA mutated colon cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002387-32 Sponsor Protocol Number: UoL001019 Start Date*: 2014-08-05
    Sponsor Name:University of Liverpool
    Full Title: Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis
    Medical condition: Aminoglycoside-induced nephrotoxicity
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    18.0 10022891 - Investigations 10069022 Kidney injury molecule-1 PT
    18.0 100000004857 10067571 Nephrotoxicity LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003634-93 Sponsor Protocol Number: NLG2107 Start Date*: 2018-02-28
    Sponsor Name:NewLink Genetics Corporation
    Full Title: A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo plus Pembrolizumab or Nivolumab in Adult Patients with Unresectable Stage III or Stage IV Malignant Mel...
    Medical condition: Adult Patients with Unresectable Stage III or Stage IV Malignant Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA